CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The appointments support the company's strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers.
The new leadership team brings extensive experience in finance, technology, and business development, which is expected to drive the company's pipeline forward. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, TPI 287, is an abeotaxane that stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors.
TPI 287 has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for conditions including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date, TPI 287 appears to have an excellent safety profile and high tolerability among patients.
The appointment of these executives underscores CNS Pharmaceuticals' commitment to advancing its pipeline and creating long-term value for shareholders. The company's strategic review and capital allocation priorities aim to ensure disciplined growth and operational execution as it progresses its development programs. For more information, visit the company's newsroom at https://ibn.fm/CNSP. The full press release is available at https://ibn.fm/lcSDZ.
